Anti-angiogenesis therapy has been proven to be effective in various tumor types, through targeting the cytokine VEGF; however, the promotion function of angiogenesis induced by CAF-derived miRNAs appears to be independent of VEGF, the main target of anti-angiogenesis therapy, which may be why the resistance emerges after tumor anti-angiogenesis therapy. The gene discussed is VEGFA; the disease is neoplasm.